Keywords: Merck & Co, Vorapaxar, Tredaptive, Cardiovascular events, USA, EU, Regulatory filings, Anacetrapib, Cholesterol

Merck & Co to file for approval of two heart drugs next year

Article | 28 August 2012

Print This

US drugs giant Merck & Co (NYSE: MRK) says that, following a review of the clinical trial data and discussions ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in